these data the compounds useful in this invention should be efficacious in treating autoimmune diseases multiple sclerosis and chronic inflammatory diseases such as rheumatoid arthritis all of which involve t lymphocyte mediated components activities in the human mixed lymphocyte reaction indicate that the compounds useful in the invention should be effective in preventing transplantation rejection and graft vs host disease the useful compounds active ingredients of this invention can be administered by any means that produces contact of the active ingredient with the agent 39 s site of action in the body of a mammal they can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients they can be administered alone but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice the dosage administered will be an effective amount of active ingredient and will of course vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration age health and weight of the recipient nature and extent of symptoms kind of concurrent treatment frequency of treatment and the effect desired usually a daily dosage of active ingredient per kilogram of body weight ordinarily 1 to 100 and preferably 10 to 50 milligrams per kilogram per day is.